Does GLP-1 Cause Hair Loss? What the Evidence Actually Shows

Hair loss doesn't show up in the ads, and it's not one of the "big three" side effects anyone warns you about before you start a GLP-1. But it's common enough to have generated a real, if still-developing, dermatology literature — including more than a thousand reports to the FDA's own adverse event system. Here's what's actually been documented, separate from forum anecdotes.

What the FDA's own safety monitoring shows

The FDA's Adverse Event Reporting System (FAERS) has logged over 1,000 spontaneous reports of hair loss associated with GLP-1 receptor agonist use, a volume large enough that dermatology researchers have started systematically reviewing it rather than treating individual reports as noise¹. A 2025 scoping review synthesizing nine studies — randomized trials, cohort data, and pharmacovigilance reports through May 2025 — found that "telogen effluvium and androgenetic alopecia" were the most frequently identified hair loss subtypes among GLP-1 users, and concluded that "GLP-1RAs may alter the hair follicle cycle," while stressing that "although a causal relationship cannot be confirmed, the recurrence of cases across diverse settings signals a potential safety concern that warrants clinical attention"¹. A separate 2025 systematic review focused specifically on tirzepatide, covering five studies and 2,905 patients, found genuinely mixed results — some data pointing toward hair loss as an adverse effect, other data suggesting improvement — and the authors were candid that the evidence doesn't yet resolve the question, concluding "further research is recommended to clarify the relationship between GLP-1 RAs and alopecia"².

What the drug labels themselves report

The clearest hard numbers come from the pivotal trials themselves, not observational data. On Zepbound, the FDA label reports injection site reactions running 6-8% across doses, and hair loss specifically at 4-5% versus 1% on placebo — with the label noting directly that hair loss "tracked with the amount of weight lost and was more common in women," a detail covered in full in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported. That single sentence in the label is doing a lot of work: it's the strongest evidence pointing away from a direct hormonal or drug-specific mechanism and toward the far more mundane, well-established phenomenon of telogen effluvium — hair shedding triggered by rapid weight loss or caloric deficit from any cause, not unique to GLP-1s.

The likely mechanism: it's about the rate of weight loss, not the drug itself

Telogen effluvium is a well-characterized condition where a physiological stressor — rapid weight loss, a major caloric deficit, surgery, illness, even extreme stress — pushes a larger-than-normal share of hair follicles into the "resting" phase of the growth cycle simultaneously. Those follicles shed a few months later, producing diffuse thinning rather than patchy bald spots, and it typically resolves once the triggering stressor stabilizes. That timeline and pattern is consistent with what the label data shows — hair loss correlating with how much weight was lost, not simply with drug exposure — which is the same body-composition logic covered in GLP-1 and muscle loss: what the body-composition data shows: rapid, large-magnitude weight loss carries physiological costs that are more about the rate and size of the change than about which specific drug produced it.

What the evidence doesn't yet establish

Neither of the 2025 reviews found a definitive causal mechanism, and the FAERS reports that anchor most of the signal are voluntary, unverified, and can't establish incidence rates the way a controlled trial can — the same limitation that applies to any pharmacovigilance database, a pattern also relevant to how we cover the network's own safety-signal literature in GLP-1 boxed warnings: what the label actually says. What's genuinely established is narrower but still useful: hair loss is a real, labeled side effect at a measurable rate (4-5% on Zepbound specifically), it's more common in women, and it tracks with weight-loss magnitude rather than appearing to be a fixed drug-specific risk that hits everyone equally.

What to actually do if it happens

Because the leading evidence points to telogen effluvium rather than a direct toxic effect, the standard clinical approach is largely reassurance and time — most telogen effluvium resolves within 6-12 months once weight stabilizes, without specific treatment. If you're losing weight unusually fast, a conversation with your prescriber about titration pace is worth having regardless of hair loss specifically, since a slower, more tolerable ramp-up is generally better for adherence — see GLP-1 dosing and titration: the schedule and why it matters. If hair loss is significant, sudden, patchy rather than diffuse, or isn't improving as your weight stabilizes, that's a reason to see a dermatologist rather than assume it's GLP-1-related by default — plenty of other causes of hair loss exist and shouldn't be missed by attributing everything to the medication.

Where this fits your provider decision

A program with a thin intake that never asks about your baseline nutrition, protein intake, or rate of weight loss isn't positioned to help you titrate in a way that minimizes this kind of side effect. See how we weigh real medical oversight in our Value Score methodology, and compare pricing across verified programs on our semaglutide and tirzepatide price boards.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.